Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

BMS’ Orencia

- PMLiVE

Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

Immunoglobulin G4-related disease affects approximately 20,000 people in the US

- PMLiVE

BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer

Around half of patients who undergo bladder removal surgery experience disease recurrence

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

- PMLiVE

FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours

Approximately 380,000 people in the US were affected by NETs in 2024

- PMLiVE

GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

- PMLiVE

FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome

The rare genetic disorder affects an estimated one in every 15,000 newborns in the US

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

- PMLiVE

Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM

Approximately 150,000 people in the US are affected by transthyretin amyloid cardiomyopathy

- PMLiVE

Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

An estimated three million people in the US are affected by inflammatory bowel disease

- PMLiVE

BMS granted EC approval for immunotherapy combination in liver cancer

More than 866,100 cases of the disease were diagnosed globally in 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links